Oncology Drugs Market

Global Oncology Drugs Market Size, Trends & Analysis - Forecasts to 2027 By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted Therapy & Immunotherapy), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer), By Dosage Form (Solid, Liquid, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa), Competitive Landscape Company Market Share Analysis, and Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on October 2 2024 with the latest and most recent market numbers

Oncology Drugs Market Size

The Global Oncology Drugs Market is projected to grow at a CAGR value of 11.5% from 2022 to 2027.

Oncology drugs are predominantly used to treat carcinogenic growths that result from the uncontrolled growth and division of abnormal cells within the patient’s body. Breast cancer, lung cancer, colon cancer, rectum cancer, and prostate cancer are some of the most commonly occurring cancers among the population. According to WHO, in 2020, cancer accounted for approximately 10 million deaths, or one in six deaths. Oncology drugs are used along with chemotherapy, immunotherapies, and targeted therapies among others. Anticancer drugs that are used for the treatment of cancer primarily do so by controlling or diminishing the growth of such cells but in due course, normal cells are also affected.

The market will be driven during the forecast period by a worldwide rise in cancer rates, a rise in demand for advanced therapies like targeted drug therapies, a rise in the geriatric population, and prevalent lifestyle habits like consumption of tobacco, alcohol, and lack of physical exercise.

Furthermore, expanding pharmaceutical industry and several innovations and development of advanced technologies, and a rise in cancer awareness leading to early screening and detection, are expected to boost the global market.

global oncology drugs market

COVID-19 Impact on Global Oncology Antibody Drug Conjugates Market

The outbreak of COVID-19 pandemic has impacted most industries across the world in different ways. The pandemic-induced lockdowns and restrictions have disrupted and delayed production processes and supply chains worldwide. In many cases, this has only improved the supply chain management given the essential good nature of such drugs. The pandemic has also impacted the market byways delaying in-person medical consultations and other surgeries as the immediate focus shifted to care of new virus-affected patients in overwhelming numbers.

Ukraine-Russia War Impact on Pharmaceutical Industry

The conflict between Ukraine and Russia has had a substantial influence on global trade. The oncology drugs market has surely been affected by disruption in operations in these two countries bolstered by numerous businesses' voluntary boycotting of conducting business in Russia. Due to the disruption of clinical trials and treatment procedures in Ukraine, demand for oncology drugs and other consumables used for pharmaceutical research and treatment has decreased. Because of the trade restrictions imposed on Russia, a substantial number of research and treatment institutes would witness a shortage of oncology drugs.

Oncology Drugs Market: By Drug Class

The cytotoxic drugs segment is expected to be the largest segment in the market from 2022 to 2027.

For the treatment of cancer, cytotoxic drugs are used as part of the chemotherapy treatment which is a common treatment option for the disease. These drugs help interrupt cell growth in the body thereby arresting the spread of cancer.

Oncology Drugs Market: By Therapy

The targeted therapy segment is expected to be the fastest-growing segment in the market from 2022 to 2027.

Targeted therapy is increasingly being adopted as a treatment option for cancer. It uses pharmaceutical drugs and other products to identify and block the growth of cancer cells and prevent the spread of cancer to other parts of the body. Such targeted therapy includes types like hormone therapies, signal transduction inhibitors, and apoptosis inducers among other approved types.

Oncology Drugs Market: By Indication

The breast cancer segment is expected to be the fastest-growing segment in the market from 2022 to 2027.

According to WHO, breast cancer was the most common type of cancer found worldwide in 2020 with 2.26 million new cases. Rising awareness for the same has led to increased early detection of such cases.

Oncology Drugs Market: By Dosage Form

The injectable segment is expected to be the fastest-growing segment in the market from 2022 to 2027.

Injectable doses in form of prefilled syringes are fast being adopted in growing numbers with generic versions of such drugs also being produced. The increasing adoption of biologics will also propel the growth of this segment.

Oncology Drugs Market: By Distribution Channel

The hospital pharmacies segment is expected to be the largest segment in the market from 2022 to 2027.

As demand for better healthcare infrastructure increases and the expenditure in the same also grows. This leads to a direct rise in the number of hospitals worldwide. Thus, with this, the number of hospital check-ups and consultations, and tests too increases leading to segment growth.

asia pacific oncology drugs market

Oncology Drugs Market: By Region

North America (the United States, Canada, and Mexico) will have a dominant share in the Oncology Drugs Market from 2022 to 2027. The major factor driving the growth of the market in the North American region is the rising prevalence of patients suffering from cancer among the demographic, and the increasing penetration of top players in the U.S. and Canada. The United States is expected to hold the dominant share of the market in the North American region owing to the rising prevalence of cancer, excellent healthcare facilities, and preen e of major industry players in the region.

Moreover, the Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific) region is expected to be the fastest-growing segment in the Oncology Drugs Market during the forecast period. The rapidly rising rate of the geriatric population and increasing demand for improved healthcare facilities especially in developing countries in the region are some of the drivers of the market. The presence of big pharmaceutical industries like India and China will also boost the regional market growth. China is expected to dominate the APAC market owing to the greater government spending on improving healthcare facilities within the region and the government’s initiative to improve the production of high-quality pharmaceuticals within the country.

Oncology Drugs Market Share and Competitor Analysis

F. Hoffmann-La Roche Ltd (Basel, Switzerland), Genentech, Inc., (California, United States), Novartis AG (Basel, Switzerland), Pfizer Inc., (New York, United States), Bristol-Myers Squibb Company (New York, United, States), GlaxoSmithKline plc. (Brentford, United Kingdom), Eli Lilly and, Company (Indiana, United States), AstraZeneca (Cambridge, United Kingdom), Sanofi (Paris, France), and Bayer AG (Leverkusen, Germany), among others are the key players in the global oncology drugs market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1   Research Methodology

1.1    Research Assumptions

1.2    Research Methodology

1.2.1    Estimates and Forecast Timeline

1.3    Information Procurement

1.3.1    Purchased Database

1.3.2    GME’s Internal Database

1.3.3    Primary Research

1.3.4    Secondary Sources & Third-Party Perspectives

            1.3.4.1    Company Information Sources: Annual Reports, Investor Presentation, Press Release, SEC Filing, Company Blogs & Website

           1.3.4.2 Secondary Data Sources

1.4    Information or Data Analysis

1.4.1    Data Analysis Models

1.5    Market Indication & Data Visualization

1.6    Data Validation & Publishing

1.7   Market Model

1.7.1    Model Details

              1.7.1.1 Top-Down Approach

               1.7.1.2 Bottom-Up Approach

1.8    Market Segmentation & Scope

1.9    Market Definition

Chapter 2   Executive Summary

2.1.    Global Market Outlook

2.2     Drug Class Outlook

2.3     Therapy Outlook

2.4     Indication Outlook

2.5     Dosage Form Outlook

2.6     Distribution Channel Outlook

2.7     Regional Outlook

Chapter 3   Global Oncology Drugs Market Trend Analysis

3.1. Market Introduction

3.2 Penetration & Growth Prospect Mapping

3.3 Impact of COVID-19 on the Oncology Drugs Market

3.4 Metric Data on Shipping & Logistics Industry

3.5 Market Dynamic

3.5.1 Market Driver Analysis

3.5.2 Market Restraint Analysis

3.5.3 Industry Challenges

3.5.4 Industry Opportunities

3.6    Porter’s Five Analysis

3.6.1 Supplier Power

3.6.2 Buyer Power

3.6.3 Substitution Threat

3.6.4 Threat from New Entrant

3.7 Market Entry Strategies

Chapter 4   Oncology Drugs Market: Drug Class Trend Analysis

4.1   Drug Class: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027

4.2    Cytotoxic Drugs

4.2.1    Market Estimates & Forecast Analysis of Cytotoxic Drugs Segment, By Region, 2019-2027 (USD Billion)

4.3   Targeted Drugs

4.3.1    Market Estimates & Forecast Analysis of Targeted Drugs Markets Segment, By Region, 2019-2027 (USD Billion)

4.3   Hormonal Drugs

4.3.1    Market Estimates & Forecast Analysis of Hormonal Drugs Markets Segment, By Region, 2019-2027 (USD Billion)

Chapter 5   Oncology Drugs Market: Therapy Trend Analysis

5.1    Therapy: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027

5.2    Chemotherapy

5.2.1    Market Estimates & Forecast Analysis of Chemotherapy Segment, By Region, 2019-2027 (USD Billion)

5.3    Targeted Therapy & Immunotherapy

5.3.1    Market Estimates & Forecast Analysis of Targeted Therapy & Immunotherapy Segment, By Region, 2019-2027 (USD Billion)

Chapter 6   Oncology Drugs Market: Indication Trend Analysis

6.1    Indication: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027

6.2    Lung Cancer

6.2.1    Market Estimates & Forecast Analysis of Lung Cancer Segment, By Region, 2019-2027 (USD Billion)

6.3    Stomach Cancer

6.3.1    Market Estimates & Forecast Analysis of Stomach Cancer Segment, By Region, 2019-2027 (USD Billion)

6.4    Colorectal Cancer

6.4.1    Market Estimates & Forecast Analysis of Colorectal Cancer Segment, By Region, 2019-2027 (USD Billion)

6.5    Breast Cancer

6.5.1    Market Estimates & Forecast Analysis of Breast Cancer Segment, By Region, 2019-2027 (USD Billion)

6.6    Prostate Cancer

6.6.1    Market Estimates & Forecast Analysis of Prostate Cancer Segment, By Region, 2019-2027 (USD Billion)

Chapter 7   Oncology Drugs Market: Dosage Form Trend Analysis

7.1   Dosage Form: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027

7.2    Solid                 

7.2.1    Market Estimates & Forecast Analysis of Solid Segment, By Region, 2019-2027 (USD Billion)

7.3    Liquid

7.3.1    Market Estimates & Forecast Analysis of Liquid Segment, By Region, 2019-2027 (USD Billion)

7.4    Injectable

7.4.1    Market Estimates & Forecast Analysis of Injectable Segment, By Region, 2019-2027 (USD Billion)

Chapter 8   Oncology Drugs Market: Distribution Channel Trend Analysis

8.1   Distribution Channel: Historic Data vs. Forecast Data Analysis, 2021 vs. 2028

8.2    Hospital Pharmacies       

8.2.1    Market Estimates & Forecast Analysis of Hospital Pharmacies Segment, By Region, 2019-2028 (USD Billion)

8.3    Retail Pharmacies

8.3.1    Market Estimates & Forecast Analysis of Retail Pharmacies Segment, By Region, 2019-2028 (USD Billion)

8.4    Online Pharmacies

8.4.1    Market Estimates & Forecast Analysis of Online Pharmacies Segment, By Region, 2019-2028 (USD Billion)

Chapter 9   Oncology Drugs Market, By Region

9.1    Regional Outlook

9.2    North America

9.2.1    Market Estimates & Forecast Analysis, By Country 2019-2027(USD Billion)

9.2.2    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.2.3    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.2.4    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.2.5    Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.2.6    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.2.7    U.S.

9.2.7.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.2.7.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.2.7.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.2.7.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.2.7.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.2.8    Canada

9.2.8.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.2.8.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.2.8.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.2.8.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.2.8.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.2.9    Mexico

9.2.9.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)

9.2.9.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027 (USD Billion)

9.2.9.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027 (USD Billion)

9.2.9.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.2.9.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3    Europe

9.3.1    Market Estimates & Forecast Analysis, By Country 2019-2027(USD Billion)

9.3.2    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.3    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.4    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.5    Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.6    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.7    Germany

9.3.7.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.7.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.7.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.7.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.7.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.8    UK

9.3.8.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.8.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.8.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.8.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.8.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.9    France

9.3.9.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.9.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.9.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.9.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.9.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.10    Russia

9.3.10.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.10.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.10.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.10.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.10.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.11    Italy

9.3.11.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.11.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.11.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.11.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.11.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.12    Spain

9.3.12.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.3.12.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.3.12.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.3.12.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.12.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.3.13    Rest of Europe

9.3.13.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)

9.3.13.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027 (USD Billion)

9.3.13.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027 (USD Billion)

9.3.13.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.3.13.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4    Asia Pacific

9.4.1    Market Estimates & Forecast Analysis, By Country 2019-2027(USD Billion)

9.4.2    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.4.3    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.4.4    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.4.5    Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4.6    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.7    China

9.4.7.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.4.7.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.4.7.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.4.7.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.7.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4.8    India

9.4.8.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.4.8.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.4.8.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.4.8.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.8.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4.9    Japan

9.4.9.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.4.9.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.4.9.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.4.9.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.9.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4.10    Australia

9.4.10.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.4.10.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.4.10.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.4.10.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.10.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4.11    South Korea

9.4.11.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.4.11.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.4.11.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.4.11.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.11.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.4.12    Rest of Asia Pacific

9.4.12.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)

9.4.12.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027 (USD Billion)

9.4.12.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027 (USD Billion)

9.4.12.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.4.12.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.5    Central & South America

9.5.1    Market Estimates & Forecast Analysis, By Country 2019-2027(USD Billion)

9.5.2    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.5.3    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.5.4   Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.5.5   Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.5.6   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.5.7    Brazil

9.5.7.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.5.7.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.5.7.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.5.7.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.5.7.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.5.8    Rest of Central & South America

9.5.8.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.5.8.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.5.8.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.5.8.4    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.5.8.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.6    Middle East & Africa

9.6.1    Market Estimates & Forecast Analysis, By Country 2019-2027(USD Billion)

9.6.2    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.6.3    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.6.4    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.6.5    Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.6.6    Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.6.7    Saudi Arabia

9.6.7.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.6.7.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.6.7.3   Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.6.7.4   Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.6.8.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.6.8    United Arab Emirates

9.6.8.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.6.8.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.6.8.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.6.8.4   Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.6.8.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.6.9    South Africa

9.6.9.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027(USD Billion)

9.6.9.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027(USD Billion)

9.6.9.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027(USD Billion)

9.6.9.4   Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.6.9.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

9.6.10   Rest of Middle East & Africa

9.6.10.1    Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)

9.6.10.2    Market Estimates & Forecast Analysis, By Therapy, 2019-2027 (USD Billion)

9.6.10.3    Market Estimates & Forecast Analysis, By Indication, 2019-2027 (USD Billion)

9.6.10.4   Market Estimates & Forecast Analysis, By Distribution Channel, 2019-2027(USD Billion)

9.6.10.5   Market Estimates & Forecast Analysis, By Dosage Form, 2019-2027(USD Billion)

Chapter 10   Competitive Analysis

10.1    Key Global Players, Recent Developments & their Impact on the Industry

10.2    Four Quadrant Competitor Positioning Matrix

10.2.1    Key Innovators

10.2.2    Market Leaders

10.2.3    Emerging Players

10.2.4    Market Challengers

10.3    Vendor Landscape Analysis

10.4    End-User Landscape Analysis

10.5    Company Market Share Analysis, 2021

Chapter 11   Company Profile Analysis

11.1    F. Hoffmann-La Roche Ltd.

11.1.1    Company Overview

11.1.2    Financial Analysis

11.1.3    Strategic Initiatives

11.1.4    Product Benchmarking

11.2    Genentech, Inc.

11.2.1    Company Overview

11.2.2    Financial Analysis

11.2.3    Strategic Initiatives

11.2.4    Product Benchmarking

11.3     Novartis AG

11.3.1    Company Overview

11.3.2    Financial Analysis

11.3.3    Strategic Initiatives

11.3.4    Product Benchmarking

11.4    Pfizer Inc.

11.4.1    Company Overview

11.4.2    Financial Analysis

11.4.3    Strategic Initiatives

11.4.4    Product Benchmarking

11.5    Bristol-Myers Squibb Company

11.5.1    Company Overview

11.5.2    Financial Analysis

11.5.3    Strategic Initiatives

11.5.4    Product Benchmarking

11.6     GlaxoSmithKline PLC

11.6.1    Company Overview

11.6.2    Financial Analysis

11.6.3    Strategic Initiatives

11.6.4    Product Benchmarking

11.7    Eli Lilly and, Company

11.7.1    Company Overview

11.7.2    Financial Analysis

11.7.3    Strategic Initiatives

11.7.4    Product Benchmarking

11.8    AstraZeneca

11.8.1    Company Overview

11.8.2    Financial Analysis

11.8.3    Strategic Initiatives

11.8.4    Product Benchmarking

11.9   Sanofi

11.9.1    Company Overview

11.9.2    Financial Analysis

11.9.3    Strategic Initiatives

11.9.4    Product Benchmarking

11.10   Bayer AG

11.10.1    Company Overview

11.10.2    Financial Analysis

11.10.3    Strategic Initiatives

11.10.4    Product Benchmarking

11.11   Other Companies

11.11.1    Company Overview

11.11.2    Financial Analysis

11.11.3    Strategic Initiatives

11.11.4    Product Benchmarking

List of Tables

1 Technological Advancements in Oncology Drugs Market

2 Global Oncology Drugs Market: Key Market Drivers

3 Global Oncology Drugs Market: Key Market Challenges

4 Global Oncology Drugs Market: Key Market Opportunities

5 Global Oncology Drugs Market: Key Market Restraints

6 Global Oncology Drugs Market Estimates & Forecast Analysis, 2019-2027 (USD Billion)

7 Global Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

8 Cytotoxic Drugs: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

9 Targeted Drugs: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

10 Hormonal Drugs: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

11 Global Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

12 Chemotherapy: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

13 Targeted Therapy & Immunotherapy: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

14 Global Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

15 Lung Cancer: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

16 Stomach Cancer: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

17 Colorectal Cancer: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

18 Breast Cancer: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

19 Prostate Cancer: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

20 Global Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

21 Solid: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

22 Liquid: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

23 Injectable: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

24 Regional Analysis: Global Oncology Drugs Market, By Region, 2019-2027 (USD Billion)

25 North America: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

26 North America: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

27 North America: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

28 North America: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

29 North America: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

30 North America: Oncology Drugs Market, By Country, 2019-2027 (USD Billion)

31 U.S: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

32 U.S: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

33 U.S: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

34 U.S: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

35 U.S: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

36 Canada: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

37 Canada: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

38 Canada: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

39 Canada: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

40 Canada: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

41 Mexico: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

42 Mexico: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

43 Mexico: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

44 Mexico: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

45 Mexico: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

46 Europe: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

47 Europe: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

48 Europe: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

49 Europe: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

50 Europe: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

51 Germany: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

52 Germany: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

53 Germany: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

54 Germany: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

55 Germany: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

56 UK: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

57 UK: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

58 UK: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

59 UK: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

60 UK: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

61 France: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

62 France: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

63 France: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

64 France: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

65 France: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

66 Italy: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

67 Italy: Oncology Drugs Market, By T Therapy Ype, 2019-2027 (USD Billion)

68 Italy: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

69 Italy: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

70 Italy: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

71 Spain: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

72 Spain: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

73 Spain: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

74 Spain: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

75 Spain: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

76 Rest Of Europe: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

77 Rest Of Europe: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

78 Rest Of Europe: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

79 Rest of Europe: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

80 Rest of Europe: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

81 Asia Pacific: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

82 Asia Pacific: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

83 Asia Pacific: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

84 Asia Pacific: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

85 Asia Pacific: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

86 Asia Pacific: Oncology Drugs Market, By Country, 2019-2027 (USD Billion)

87 China: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

88 China: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

89 China: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

90 China: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

91 China: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

92 India: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

93 India: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

94 India: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

95 India: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

96 India: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

97 Japan: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

98 Japan: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

99 Japan: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

100 Japan: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

101 Japan: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

102 South Korea: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

103 South Korea: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

104 South Korea: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

105 South Korea: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

106 South Korea: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

107 Middle East & Africa: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

108 Middle East & Africa: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

109 Middle East & Africa: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

110 Middle East & Africa: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

111 Middle East & Africa: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

112 Middle East & Africa: Oncology Drugs Market, By Country, 2019-2027 (USD Billion)

113 Saudi Arabia: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

114 Saudi Arabia: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

115 Saudi Arabia: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

116 Saudi Arabia: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

117 Saudi Arabia: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

118 UAE: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

119 UAE: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

120 UAE: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

121 UAE: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

122 UAE: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

123 Central & South America: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

124 Central & South America: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

125 Central & South America: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

126 Central & South America: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

127 Central & South America: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

128 Central & South America: Oncology Drugs Market, By Country, 2019-2027 (USD Billion)

129 Brazil: Oncology Drugs Market, By Drug Class, 2019-2027 (USD Billion)

130 Brazil: Oncology Drugs Market, By Therapy, 2019-2027 (USD Billion)

131 Brazil: Oncology Drugs Market, By Indication, 2019-2027 (USD Billion)

132 Brazil: Oncology Drugs Market, By Distribution Channel, 2019-2027 (USD Billion)

133 Brazil: Oncology Drugs Market, By Dosage Form, 2019-2027 (USD Billion)

134 F. Hoffmann-La Roche Ltd.: Products Offered

135 Genentech, Inc.: Products Offered

136 Novartis AG: Products Offered

137 Pfizer Inc.: Products Offered

138 Bristol-Myers Squibb Company: Products Offered

139 GlaxoSmithKline PLC: Products Offered

140 Eli Lilly and, Company: Products Offered

141 AstraZeneca: Products Offered

142 Sanofi: Products Offered

143 Bayer AG: Products Offered

144 Other Companies: Products Offered

List of Figures

1. Global Oncology Drugs Market  Segmentation & Research Scope

2. Primary Research Partners and Local Informers

3. Primary Research Process

4. Primary Research Approaches

5. Primary Research Responses

6. Global Oncology Drugs Market: Penetration & Growth Prospect Mapping

7. Global Oncology Drugs Market: Value Chain Analysis

8. Global Oncology Drugs Market Drivers

9. Global Oncology Drugs Market Restraints

10. Global Oncology Drugs Market Opportunities

11. Global Oncology Drugs Market Challenges

12. Key Oncology Drugs Market Manufacturer Analysis

13. Global Oncology Drugs Market: Porter’s Five Forces Analysis

14. PESTLE Analysis & Impact Analysis

15. F. Hoffmann-La Roche Ltd.: Company Snapshot

16. F. Hoffmann-La Roche Ltd.: Swot Analysis

17. Genentech, Inc.: Company Snapshot

18. Genentech, Inc.: Swot Analysis

19. Novartis AG: Company Snapshot

20. Novartis AG: Swot Analysis

21. Pfizer Inc.: Company Snapshot

22. Pfizer Inc.: Swot Analysis

23. Bristol-Myers Squibb Company: Company Snapshot

24. Bristol-Myers Squibb Company: Swot Analysis

25. GlaxoSmithKline PLC: Company Snapshot

26. GlaxoSmithKline PLC: Swot Analysis

27. Eli Lilly and, Company: Company Snapshot

28. Eli Lilly and, Company: Swot Analysis

29. AstraZeneca: Company Snapshot

30. AstraZeneca: Swot Analysis

31. Sanofi: Company Snapshot

32. Sanofi: Swot Analysis

33. Bayer AG: Company Snapshot

34. Bayer AG: Swot Analysis

35. Other Companies: Company Snapshot

36. Other Companies: Swot Analysis

The Global Oncology Drugs Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Oncology Drugs Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global oncology drugs market?
F. Hoffmann-La Roche Ltd (Basel, Switzerland) Genentech, Inc., (California, United States) Novartis AG (Basel, Switzerland) Pfizer Inc., (New York, United States) Bristol-Myers Squibb Company (New York, United, States) GlaxoSmithKline plc. (Brentford, United Kingdom) Eli Lilly and, Company (Indiana, United States) AstraZeneca (Cambridge, United Kingdom), Sanofi (Paris, France) Bayer AG (Leverkusen, Germany), among others are the key players in the global oncology drugs market.
The outbreak of COVID-19 pandemic has impacted most industries across the world in different ways. The pandemic-induced lockdowns and restrictions have disrupted and delayed production processes and supply chains worldwide. In many cases, this has only improved the supply chain management given the essential good nature of such drugs. The pandemic has also impacted the market byways delaying in-person medical consultations and other surgeries as the immediate focus shifted to care of virus-affected patients in overwhelming numbers.
The market will be driven during the forecast period by a worldwide rise in cancer rates, a rise in demand for advanced therapies like targeted drug therapies, a rise in the geriatric population, and prevalent lifestyle habits like consumption of tobacco, alcohol, and lack of physical exercise. Other drivers include an expanding pharmaceutical industry and several innovations and development of advanced technologies, and a rise in cancer awareness leading to early screening and detection.
The conflict between Ukraine and Russia has had a substantial influence on global trade. The oncology drugs market has surely been affected by disruption in operations in these two countries bolstered by numerous businesses voluntary boycotting of conducting business in Russia. Due to the disruption of clinical trials and treatment procedures in Ukraine, demand for oncology drugs and other consumables used for pharmaceutical research and treatment has decreased. Because of the trade restrictions imposed on Russia, a substantial number of research and treatment institutes would witness a shortage of oncology drugs.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius